Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
Commercial Sponsor
Telios Pharma, Inc.
Summary
This is a non-randomised, open-label trial with one experimental arm. Participants will receive TL-895, administered orally, twice daily, continuously starting on Day 1 in a 28-day cycle, in combination with KRT-232, administered orally, once daily, on days 1-7 in a 28-day cycle.